Kintara Therapeutics, Inc.

  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
    • Academic Collaborations
    • Advisors
  • Pipeline
    • Overview
    • VAL-083
    • REM-001
  • Clinical Trials
  • News & Media
    • Press Releases
    • Publications and Abstracts
    • Presentations
    • Events
    • Recent News
  • Investors
    • Overview
    • Analyst Coverage
    • News / Events
    • Company Information
    • Stock Data
    • SEC Filings
    • Corporate Governance
  • Contact
  • Careers

Press Releases

Investors

Investors

  • Overview
  • Analyst Coverage
  • News / Events
    • Overview
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Company Info
    • Overview
    • Profile
    • Presentations
    • Management Team
    • Contacts
    • FAQ
  • Stock Data
    • Overview
    • Quote
    • Charts
    • Historical Data
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
    • Independent Directors
  • Investor Tools
    • Email Alerts
    • Contacts
    • RSS News Feed
  • News / Events

  • Overview
  • Press Releases
  • IR Calendar
  • Email Alerts

DelMar Pharmaceuticals Announces Second Quarter Fiscal Year 2018 Financial Results

Feb 14, 2018

DelMar Pharmaceuticals Announces Fast Track Designation for VAL-083 in Recurrent Glioblastoma

Dec 26, 2017

DelMar Presents Positive Interim Results from VAL-083 Study in MGMT-unmethylated Recurrent GBM at The Society for NeuroOncology Annual Meeting

Nov 21, 2017

DelMar Pharmaceuticals Announces First Quarter Fiscal Year 2018 Financial Results

Nov 13, 2017

DelMar Pharmaceuticals Appoints Saiid Zarrabian as Interim Chief Executive Officer

Nov 7, 2017

DelMar Pharmaceuticals Presents Data Supporting VAL-083 as a Component of Combination Chemotherapy Regimens for the Treatment of Solid Tumors including Brain and Ovarian Cancer

Oct 31, 2017

DelMar Pharmaceuticals Presents Poster at AACR's Ovarian Cancer Special Conference on the Mechanistic Rationale for VAL-083 Overcoming Treatment Resistance in Ovarian Cancer

Oct 3, 2017

DelMar Pharmaceuticals Announces Fiscal Year 2017 Financial Results

Sep 28, 2017

DelMar Pharmaceuticals to Present at AACR Special Conference on Ovarian Cancer

Sep 27, 2017

DelMar Pharmaceuticals Announces Closing Of $10 Million Registered Direct Offering Priced At-The-Market

Sep 22, 2017
RSS
    • 1...
    • 4
    • 5
    • 6
    • 7
    • 8
    • 9
    • 10
    • 11
    • 12
    • 13
    • ...28
    © 2021 Kintara Therapeutics, Inc. All Rights Reserved.
    Privacy Policy Disclaimer Sitemap Legal Information